ISRCTN15067672 https://doi.org/10.1186/ISRCTN15067672

A randomised multicenter clinical trial for patients with multi-organ, colorectal cancer metastases comparing the combination of chemotherapy and removing as many visible tumors as possible by surgery or other means versus chemotherapy alone

Submission date 27/01/2020	<b>Recruitment status</b> No longer recruiting	<ul> <li>Prospectively registered</li> <li>Protocol</li> </ul>
<b>Registration date</b> 07/02/2020	<b>Overall study status</b> Completed	<ul> <li>[_] Statistical analysis plan</li> <li>[X] Results</li> </ul>
Last Edited 04/03/2025	<b>Condition category</b> Cancer	Individual participant data

### Plain English summary of protocol

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-atchemotherapy-with-other-treatments-for-bowel-cancer-that-has-spread-orchestra

### Study website

https://dccg.nl/trial/orchestra

# **Contact information**

**Type(s)** Scientific

**Contact name** Dr Lotte Bakkerus

ORCID ID http://orcid.org/0000-0002-7168-3799

### **Contact details**

Geert Grooteplein Zuid 10 Department Medical Oncology Route 452 Nijmegen Netherlands 6525 GA +31 (0)6 21000287 Lotte.bakkerus@radboudumc.nl

# Additional identifiers

EudraCT/CTIS number 2011-005003-32

**IRAS number** 255338

ClinicalTrials.gov number NCT01792934

Secondary identifying numbers CPMS 43762, IRAS 255338

# Study information

### Scientific Title

A randomized multicenter clinical trial for patients with multi-organ, colorectal cancer metastases comparing the combination of chemotherapy and maximal tumor debulking versus chemotherapy alone

### Acronym

ORCHESTRA

### **Study objectives**

Colorectal cancer is the third most common malignancy worldwide and the second leading cause of cancer death in the United Kingdom. In both early stage and metastatic disease, curative treatment is only possible with complete resection of the tumor. In recent years, resection of single organ metastases has improved survival in patients with limited metastatic colorectal cancer. Besides surgical resection, several techniques have become available for local treatment of metastases, including radiofrequency ablation, stereotactic ablative radiotherapy and transarterial chemoembolization. Local treatment of metastases of patients with metastatic colorectal cancer is often technically feasible, but effects on survival and quality of life have not been studied in patients with multi-organ metastatic colorectal cancer. The standard treatment of multi-organ metastasized colorectal cancer is systemic chemotherapy. This study is a randomized multicenter clinical trial for patients with multi-organ metastatic colorectal cancer, comparing the combination of chemotherapy and maximal tumor debulking versus chemotherapy alone. It is hypothesized that adding tumor debulking to chemotherapy will increase overall survival with at least six months.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 26/11/2019, North East – Tyne & Wear South Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Address: Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; Tel:

+44 (0)207 1048084; Email: nrescommittee.northeast-tyneandwearsouth@nhs.net), ref: 19/NE /0261

### Study design

Randomised; Interventional; Design type: Treatment, Radiotherapy, Surgery

**Primary study design** Interventional

### Secondary study design

Randomised controlled trial

#### Study setting(s) Hospital

Study type(s)

Treatment

## Participant information sheet

See additional files

### Health condition(s) or problem(s) studied

Multi-organ, colorectal cancer metastases

#### Interventions

All patients will receive 3 cycles of chemotherapy with the XELOX regimen (capecitabine and oxaliplatin; 3-week cycle) or 4 cycles of FOLFOX regimen (5-FU and oxaliplatin; 2-week cycle) with or without bevacizumab. A baseline CT or 18F-FDG-PET-CT will be performed no more than 28 days prior to the first dose of chemotherapeutic treatment. After 3 or 4 cycles of XELOX or FOLFOX respectively, a second CT or 18F-FDG-PET-CT will be made and response rates will be evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). When required for assessing response rates, an MRI scan will be performed. Patients who show clinical benefit, defined as stable disease or response to therapy, will be randomized in one of the two study arms, arm A and arm B. Patients with progressive disease are not eligible study participation and will be treated according to best clinical practice, including all treatment modalities.

A CT or 18F-FDG-PET-CT, laboratory analysis, tumor markers and quality of life and multidimensional fatigue inventory questionnaires will be obtained at baseline, after 3 or 4 cycles of chemotherapy and subsequently every three months will be done.

Patients included in study arm A will continue to receive XELOX or FOLFOX therapy with or without bevacizumab until disease progression or unacceptable therapy-related toxicity. After 6 cycles of XELOX or FOLFOX, capecitabine monotherapy is also allowed. In case of unacceptable toxicity of oxaliplatin, capecitabine monotherapy may be considered before 6 cycles of XELOX or FOLFOX. When patients show progressive disease, they will be treated with second line therapy according to best clinical practice. Palliative local treatment options are accepted for a single progressive metastasis or for symptomatic metastases.

Patients in study arm B will be treated with 1 additional cycle of XELOX or FOLFOX without bevacizumab and additional local treatment in case of >30% response rates. Preferred local treatment will be surgical resection of the tumor lesions. Technically unresectable tumor lesions

will be treated within 4 weeks by any form of other local treatment i.e. RFA, (DEBIRI-)TACE or SABR, depending on best clinical judgment and depending on the metastatic site. After local treatment, patients will receive 8 to12 additional cycles of XELOX or corresponding FOLFOX therapy with or without bevacizumab. After a total of 6 cycles of XELOX or FOLFOX, monotherapy with capecitabine is allowed. In case of unacceptable toxicity XELOX or FOLFOX therapy will be withheld. In case of unacceptable toxicity of oxaliplatin, monotherapy with capecitabine may be considered.

Patients in study arm B with stable disease will receive 3 additional cycles of XELOX or 4 cycles of FOLFOX with or without bevacizumab, whereafter response rates will be reevaluated. When these patients show a response or stable disease at this reevaluation they will be subjected to 1 additional cycle of XELOX or FOLFOX without bevacizumab and local treatment as described above. After local treatment, patients will receive 4 to 8 additional cycles of XELOX or corresponding FOLFOX therapy with or without bevacizumab. In case of unacceptable toxicity XELOX or FOLFOX therapy will be withheld. In case of unacceptable toxicity of oxaliplatin, capecitabine monotherapy may be considered. Patients with progressive disease will be treated according to best clinical practice, including all treatment modalities. It is recommended to continue treatment until disease progression or unacceptable toxicity. However, continuation of any treatment schedule after 6 months in absence of disease progression or unacceptable toxicity is at the discretion of the investigator.

After local treatment, patients in study arm B will receive additional cycles of XELOX or corresponding FOLFOX therapy with or without bevacizumab to complete a minimum of 8 cycles of XELOX (or a corresponding 12 cycles of FOLFOX) or until disease progression or unacceptable toxicity. Patients with progressive disease will be treated according to best clinical practice, including all treatment modalities.

The primary endpoint of the study is overall survival. The study will be successful if at least a 6month OS benefit is demonstrated in the experimental arm. In this randomized controlled trial the ratio of experimental versus control arm is 1:1. Using the log-rank test this trial will have 80% power to show this difference in OS with a 5% type I error rate (two-sided) when a minimum of 382 patients are enrolled with a follow-up time of 24 months.

#### Intervention Type

Mixed

### Primary outcome measure

Overall survival (OS), counting from the date of study inclusion to the date of death of the patient

### Secondary outcome measures

1. Progression-free survival measured using the inclusion date and the progression date. Progression measured using RECIST 1.1 scoring system for each CT scan at baseline, randomization (after 3 or 4 cycles of chemotherapy) and every 3 months until progressive disease

2. Safety and efficacy of additional local treatment measured using scoring of Serious Adverse Events using the CTCAE version 4 and Clavien Dindo scoring systems when a SAE occurred 3. Quality of life measured using the validated EORTC QLQ CR29 and C30 questionaires at baseline, randomization (after 3 or 4 cycles of chemotherapy) and every 3 months until progressive disease

# Overall study start date

14/06/2012

Completion date 01/07/2025

# Eligibility

### Key inclusion criteria

1. Patients with CRC metastases in  $\geq$  2 different organs and

1.1. >3 extrahepatic metastases or

1.2. >5 hepatic metastases not located to one lobe or

1.3. ≥1 hepatic metastases and either positive para-aortal lymph nodes or celiac lymph nodes or adrenal metastases or pleural carcinomatosis or peritoneal carcinomatosis

1.4. The primary tumor is excluded as metastatic site

2. Feasible radical tumor debulking. Incomplete tumor debulking is allowed only if at least 80% of metastases can be treated

3. Age >= 18 years

4. WHO performance status 0 – 1

5. Life expectancy of at least 12 weeks

6. Written informed consent

Participant type(s)

Patient

**Age group** Adult

**Lower age limit** 18 Years

Sex

Both

Target number of participants

Planned Sample Size: 478; UK Sample Size: 70

### Key exclusion criteria

1. Prior (neo-)adjuvant chemotherapy for < 6 months after last treatment and first detection of extrahepatic metastases, except for neoadjuvant capecitabin in the context of chemoradiation for rectal carcinoma

2. Candidates for HIPEC

3. Patients with liver metastases only

4. Evidence of brain metastases

5. History of other prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in-situ carcinoma of any organ. Patients with other malignancies are eligible if they have remained disease free for at least 5 years

6. History of cardiac disease:

6.1. Congestive heart failure >NYHA class 2

6.2. Active Coronary Artery Disease (defined as myocardial infarction within 6 months prior to

screening)

6.3. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)

7. Uncontrolled hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 3 separate measurements on at least 2 separate days

8. Uncontrolled infections (> grade 2 NCI-CTC version 4.0)

9. Pregnant or breastfeeding women. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must agree to use adequate barrier birth control measures (e.g., cervical cap, condom, and diaphragm) or intrauterine device during the course of the trial. Oral birth control methods alone will not be considered adequate on this study, because of the potential pharmacokinetic interaction between study drug and oral contraceptives. Concomitant use of oral and barrier contraceptives is advised.

10. Concurrent anticancer chemotherapy, immunotherapy or investigational drug therapy during the study or within 4 weeks of the start of study drug

11. Concomitant chronic use of dexamethasone, anti-convulsants and anti-arrhythmic drugs other than digoxin or beta blockers

12. Severe allergy for contrast media not controlled with premedication

13. Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results

14. Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study

Date of first enrolment 01/05/2013

Date of final enrolment

01/07/2023

# Locations

**Countries of recruitment** England

Netherlands

United Kingdom

#### Study participating centre University Hospital Southampton NHS Foundation Trust Mailpoint 18 Southampton General Hospital Tremona Road Southampton United Kingdom SO16 6YD

**Study participating centre Royal Free London NHS Foundation Trust** Royal Free Hospital Pond Street London United Kingdom NW3 2QG

**Study participating centre Royal Liverpool and Broadgreen University Hospitals NHS Trust** Royal Liverpool University Hospital Prescot Street Liverpool United Kingdom L7 8XP

**Study participating centre Hampshire Hospitals NHS Foundation Trust** Aldermaston Road Basingstoke United Kingdom RG24 9NA

## Sponsor information

**Organisation** Radboud University Medical Centre Nijmegen (Netherlands)

#### Sponsor details

c/o H. Verheul Geert Grooteplein Zuid 10 Nijmegen Netherlands 6525 GA +31 (0)243618800 henk.verheul@radboudumc.nl

**Sponsor type** Hospital/treatment centre

# Funder(s)

Funder type Charity

**Funder Name** KWF Kankerbestrijding

Alternative Name(s) The Dutch Cancer Society, Koningin Wilhelmina Fonds, DCS, KWF

**Funding Body Type** Private sector organisation

**Funding Body Subtype** Other non-profit organizations

**Location** Netherlands

# **Results and Publications**

### Publication and dissemination plan

- 1. The protocol is available at: https://dccg.nl/trial/orchestra
- 2. Peer-reviewed scientific journals
- 3. Internal report
- 4. Conference presentation
- 5. Publication on website

#### Intention to publish date

30/12/2024

### Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication

#### IPD sharing plan summary

Other

#### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	version v3	01/10/2019	07/02/2020	No	Yes
HRA research summary			28/06/2023	No	No
Abstract results		05/06/2024	04/03/2025	No	No